美国肺癌早期诊断比例的时间趋势(2003-2022)
该描述性监测研究基于美国癌症统计数据,分析2003至2022年4 363 687例新发肺癌病例。早期诊断比例从2003年的17.6%升至2022年的30.1%,多数州约自2016年起明显上升。研究提示2013年肺癌筛查推荐后早期诊断比例提高,但2024年符合条件者筛查覆盖率仍不足五分之一。
要点
- 2003至2022年美国肺癌早期诊断比例由17.6%升至30.1%。
- 2015至2016年早期诊断比例出现明显跃升,多数州约自2016年起上升。
- 2024年符合筛查条件人群中报告筛查达标者不足五分之一。
核心结论
- 自2013年推荐肺癌筛查以来,美国肺癌早期诊断比例持续上升,但符合条件人群的筛查覆盖率仍偏低。
研究设计与样本
- 描述性监测研究,使用美国癌症统计数据,纳入2003至2022年诊断为恶性肺癌的美国成人,共4 363 687例新发病例。
- 数据于2025年11月14日至11月30日分析。
主要发现
- 早期诊断比例从2003年的17.6%(95% CI,17.5%-17.8%)缓慢升至2014年的20.2%(95% CI,20.0%-20.4%)。
- 2015年的21.4%(95% CI,21.2%-21.6%)到2016年 sharp 升至24.6%(95% CI,24.4%-24.8%),随后稳步升至2022年的30.1%(95% CI,29.9%-30.3%)。
- 所有州的早期诊断比例均上升,多数州约自2016年开始上升。
- 2003年各州早期诊断比例范围为11.2%(95% CI,8.5%-14.6%)至24.0%(95% CI,22.7%-25.4%)。
- 2022年该范围变为22.0%(95% CI,18.9%-25.5%)至40.2%(95% CI,36.7%-43.9%)。
临床怎么用
- 提示应加强公众对肺癌筛查获益的认知并支持筛查 uptake,作为癌症预防与控制的重要策略。
- 关注本地区早期诊断比例的时间变化,评估筛查实施效果。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Since December 2013, the US Preventive Services Task Force has recommended lung cancer screening for adults at high risk of developing lung cancer because of their age and smoking history. Increased uptake in lung cancer screening may be reflected in changes in the stage at which lung cancer is diagnosed. OBJECTIVE: To examine the percentage of lung cancer cases diagnosed at an early stage, visualizing temporal patterns with heat maps. DESIGN, SETTING, AND PARTICIPANTS: This descriptive surveillance study used US Cancer Statistics incidence data to identify US adults who were diagnosed with malignant lung cancer from 2003 to 2022. Data were analyzed from November 14 to November 30, 2025. MAIN OUTCOMES AND MEASURES: Percentage of lung cancers diagnosed at early stage, stratified by year of diagnosis, age at diagnosis, and state of residence. RESULTS: From 2003 to 2022, 4 363 687 new lung cancer cases were reported in the US. The percentage diagnosed at early stage increased slowly from 17.6% (95% CI, 17.5%-17.8%) in 2003 to 20.2% (95% CI, 20.0%-20.4%) in 2014, increased sharply from 21.4% (95% CI, 21.2%-21.6%) in 2015 to 24.6% (95% CI, 24.4%-24.8%) in 2016, then increased steadily to 30.1% (95% CI, 29.9%-30.3%) in 2022. The percentage diagnosed at early stage increased in all states, beginning around 2016 in most states. In 2003, the percentage diagnosed at early stage ranged from 11.2% (95% CI, 8.5%-14.6%) to 24.0% (95% CI, 22.7%-25.4%); by 2022, this range was 22.0% (95% CI, 18.9%-25.5%) to 40.2% (95% CI, 36.7%-43.9%). CONCLUSIONS AND RELEVANCE: This descriptive surveillance study showed that since lung cancer screening was recommended in 2013, more people with lung cancer are being diagnosed early, when treatment is more effective and more treatment options are available. Population-based survey data indicate that fewer than 1 in 5 eligible persons reported being up to date with lung cancer screening in 2024. Strengthening awareness about the benefits of lung cancer screening and supporting uptake remain important strategies for cancer prevention and control.
引用
- Henley SJ, Adam EE, Kava CM, et al. Temporal Trends in Lung Cancer Cases Diagnosed at Early Stage. JAMA Oncol. 2026. PMID: 42133301. doi:10.1001/jamaoncol.2026.1199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。